Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432845 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRKDM4EERN1PTPN1 | |
| SCHEMBL1350147 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TSHRKDM4EERN1PTPN1 | |
| SCHEMBL28653350 | 0.79 | TNKS2 (0.51) | ALDH1A1TSHRERN1PTPN1 | |
| SCHEMBL4363014 | 0.78 | ERN1 (0.46) | ALDH1A1KDM4EERN1PTPN1MEN1 | |
| SCHEMBL29957006 | 0.78 | ERN1 (0.46) | ALDH1A1KDM4EERN1PTPN1MEN1 | |
| SCHEMBL12958097 | 0.77 | MEN1 (0.37) | MEN1KMT2APTGS1PTGS2HDAC4 | |
| SCHEMBL16950812 | 0.77 | PTGS1 (0.41) | PTGS1PTGS2HDAC4NFE2L2SLC9A1 | |
| SCHEMBL7826401 | 0.77 | PTGS1 (0.41) | MEN1KMT2APTGS1PTGS2HDAC4 | |
| SCHEMBL65723 | 0.76 | ERN1 (0.56) | ALDH1A1KDM4EERN1PTPN1NFE2L2 | |
| SCHEMBL268706 | 0.76 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM4EERN1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409595-A | 1-styryl isoquinoline derivative and preparation and application thereof | 南华大学附属第一医院 | 2022-04-29 | — | — | CN | claimed |
| CN-1183134-C | Tricyclic vasopressin agonists | — | 2005-01-05 | — | — | CN | claimed |
| EP-0560268-B1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-04 | — | — | EP | claimed |
| WO-1993018003-A1 | SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024131448-A1 | INDOLIN-2-ONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 沈阳药科大学 | 2024-06-27 | — | — | WO | disclosed |
| CN-118221652-A | Indol-2-one derivative and preparation method and application thereof | 沈阳药科大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-114409595-B | 1-Styryl isoquinoline derivative and preparation and application thereof | 南华大学附属第一医院 | 2024-05-14 | — | — | CN | disclosed |
| US-4448971-A | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4407811-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4399296-A | TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4367234-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-01-04 | — | — | US | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | ALDH1A1 3684/4885TSHR 4270/4885KDM4E 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.